Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Neoplasm Metastasis 39Lymphoma 27Multiple Myeloma 24Colorectal Neoplasms 20Leukemia, Myeloid, Acute 18Melanoma 13Lung Neoplasms 13Prostatic Neoplasms 12Pancreatic Neoplasms 12Ovarian Neoplasms 12Breast Neoplasms 11Sarcoma 10Triple Negative Breast Neoplasms 9Lymphoma, Non-Hodgkin 9Fallopian Tube Neoplasms 9Burkitt Lymphoma 9Urinary Bladder Neoplasms 8Neuroblastoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Glioma 8Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 7Myelodysplastic Syndromes 7Lymphoma, Follicular 7Endometrial Neoplasms 7Lymphoma, Large B-Cell, Diffuse 6Cholangiocarcinoma 6Central Nervous System Neoplasms 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5

Interventions

Specimen Handling 6cabozantinib 4Magnetic Resonance Spectroscopy 4Trastuzumab 3Gemcitabine 3Biopsy 3eribulin 2atezolizumab 2Nivolumab 2Ipilimumab 2CTLA-4 Antigen 2tipifarnib 1pazopanib 1ixabepilone 1erdafitinib 1entinostat 1enfortumab vedotin 1avelumab 1aflibercept 1Sunitinib 1Sorafenib 1Platinum 1Lenalidomide 1Interleukin-7 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunohistochemistry 1Immunoglobulin G 1Fluorouracil 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Urethral Neoplasms × Biopsy × Clear all
NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
152 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT03237780 2026-05-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 14 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡